Healthcare Professional Check

This website is intended for diabetes healthcare professionals. Click one of the options below to access the content.

You are here

Insulin detemir: A historical perspective on a modern basal insulin analogue

Primary Care Diabetes, pages S31 - S42

Abstract

Insulin detemir provides prolonged, reproducible blood glucose reduction through a mechanism unique among basal insulins. It was originally studied clinically in predominantly basal + bolus regimens and found to be associated with a low risk of hypoglycaemia compared to insulin NPH, and reduced weight gain compared to other basal insulins. Insulin detemir has been increasingly studied in basal-only insulin regimens in type 2 diabetes, in which an understanding of how to optimize its use has been built incrementally. Glycaemic control and limitation of weight gain tend to be maximized by once-daily (evening) dosing, earlier initiation and careful titration to appropriate fasting glucose targets.

Keywords: Insulin detemir, Basal insulin analogue, Hypoglycemia, Weight gain.

References

  • 1 M. Bliss. Resurrections in Toronto: the emergence of insulin. Horm. Res.. 2005;64(Suppl. 2):98-102
  • 2 A. Lindholm. New insulins in the treatment of diabetes mellitus. Best Pract. Res. Clin. Gastroenterol.. 2002;16:475-492
  • 3 S.O. Emdin, G.G. Dodson, J.M. Cutfield, S.M. Cutfield. Role of zinc in insulin biosynthesis. Some possible zinc-insulin interactions in the pancreatic B-cell. Diabetologia. 1980;19:174-182
  • 4 P. Hildebrandt, P. Sejrsen, S.L. Nielsen, et al. Diffusion and polymerization determines the insulin absorption from subcutaneous tissue in diabetic patients. Scand. J Clin. Lab. Invest.. 1985;45:685-690
  • 5 S. Kang, J. Brange, A. Burch, et al. Subcutaneous insulin absorption explained by insulin's physicochemical properties. Evidence from absorption studies of soluble human insulin and insulin analogues in humans. Diabetes Care. 1991;14:942-948
  • 6 K.S. Polonsky, B.D. Given, E. van Cauter. Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J. Clin. Invest.. 1988;81:442-448
  • 7 M. Hanefeld, S. Fischer, U. Julius, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia. 1996;39:1577-1583
  • 8 M. Tominaga, H. Eguchi, H. Manaka, et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care. 1999;22:920-924
  • 9 DECODE study group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet. 1999;354:617-621
  • 10 P. Home, P. Kurtzhals. Insulin detemir: from concept to clinical experience. Expert Opin. Pharmacother.. 2006;7:325-343
  • 11 G.B. Bolli, D.R. Owens. Insulin glargine. Lancet. 2000;356:443-445
  • 12 S. Havelund, A. Plum, U. Ribel, et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm. Res.. 2004;21:1498-1504
  • 13 P. Kurtzhals. Engineering predictability and protraction in a basal insulin analogue: the pharmacology of insulin detemir. Int. J Obes. Relat. Metab. Disord.. 2004;28(Suppl. 2):S23-S28
  • 14 P. Kurtzhals, L. Schaffer, A. Sorensen, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes. 2000;49:999-1005
  • 15 A. Shukla, J. Grisouard, V. Ehemann, et al. Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines. Endocr. Relat. Cancer. 2009;16:429-441
  • 16 M. Lepore, S. Pampanelli, C. Fanelli, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000;49:2142-2148
  • 17 J. Plank, M. Bodenlenz, F. Sinner, et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care. 2005;28:1107-1112
  • 18 T. Heise, L. Nosek, B.B. Ronn, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004;53:1614-1620
  • 19 O. Klein, J. Lynge, L. Endahl, et al. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes. Metab.. 2007;9:290-299
  • 20 K. Kolendorf, G.P. Ross, I. Pavlic-Renar, et al. Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes. Diabet. Med.. 2006;23:729-735
  • 21 P.C. Bartley, M. Bogoev, J. Larsen, A. Philotheou. Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial. Diabet. Med.. 2008;25:442-449
  • 22 K. Hermansen, P. Fontaine, K.K. Kukolja, et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia. 2004;47:622-629
  • 23 D. Russell-Jones, R. Simpson, B. Hylleberg, et al. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. Clin Ther. 2004;26:724-736
  • 24 Centers for Disease Control. CDC fact sheet 2007. http://www.cdc.gov/diabetes/pubs/factsheet07.htm (accessed December 16, 2009).
  • 25 L.K. Khan, K. Sobush, D. Keener, et al. Recommended community strategies and measurements to prevent obesity in the United States. MMWR. Recomm. Rep.. 2009;58:1-26
  • 26 E.W. Gregg, Y.J. Cheng, K.M. Narayan, et al. The relative contributions of different levels of overweight and obesity to the increased prevalence of diabetes in the United States: 1976–2004. Prev. Med.. 2007;45:348-352
  • 27 S. Wild, G. Roglic, A. Green, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-1053
  • 28 P. Hossain, B. Kawar, M. El Nahas. Obesity and diabetes in the developing world–a growing challenge. N. Engl. J Med.. 2007;356:213-215
  • 29 M. Marcovecchio, A. Mohn, F. Chiarelli. Type 2 diabetes mellitus in children and adolescents. J. Endocrinol. Invest.. 2005;28:853-863
  • 30 P. Zeitler. Update on nonautoimmune diabetes in children. J. Clin. Endocrinol. Metab.. 2009;94:2215-2220
  • 31 D.P. Schuster. Changes in physiology with increasing fat mass. Semin. Pediatr. Surg.. 2009;18:126-135
  • 32 M. Brod, J.H. Kongso, S. Lessard, T.L. Christensen. Psychological insulin resistance: patient beliefs and implications for diabetes management. Qual. Life Res.. 2009;18:23-32
  • 33 W.T. Garvey, J.M. Olefsky, J. Griffin, et al. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes. 1985;34:222-234
  • 34 Y. Li, W. Xu, Z. Liao, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care. 2004;27:2597-2602
  • 35 R.G. Bretzel, U. Nuber, W. Landgraf, et al. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet. 2008;371:1073-1084
  • 36 R.R. Holman, K.I. Thorne, A.J. Farmer, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N. Engl. J Med.. 2007;357:1716-1730
  • 37 D.R. Owens, L.S. Cozma, S.D. Luzio. Early-phase prandial insulin secretion: its role in the pathogenesis of type 2 diabetes mellitus and its modulation by repaglinide. Diabetes Nutr. Metab.. 2002;15:19-27
  • 38 L. Blonde, M. Merilainen, V. Karwe, et al. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets – the TITRATE study. Diabetes Obes. Metab.. 2009;11:623-631
  • 39 D. Russell-Jones, R. Khan. Insulin-associated weight gain in diabetes–causes, effects and coping strategies. Diabetes Obes. Metab.. 2007;9:799-812
  • 40 W.H. Polonsky, B.J. Anderson, P.A. Lohrer, et al. Insulin omission in women with IDDM. Diabetes Care. 1994;17:1178-1185
  • 41 K.S. Bryden, A. Neil, R.A. Mayou, et al. Eating habits, body weight, and insulin misuse. A longitudinal study of teenagers and young adults with type 1 diabetes. Diabetes Care. 1999;22:1956-1960
  • 42 S. Herpertz, C. Albus, R. Wagener, et al. Comorbidity of diabetes and eating disorders. Does diabetes control reflect disturbed eating behavior?. Diabetes Care. 1998;21:1110-1116
  • 43 K. Eeg-Olofsson, J. Cederholm, P.M. Nilsson, et al. Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13,087 patients. Diabetologia. 2009;52:65-73
  • 44 J.W. Anderson, E.C. Konz. Obesity and disease management: effects of weight loss on comorbid conditions. Obes. Res.. 2001;9(Suppl. 4):326S-334S
  • 45 T. Heise, T.R. Pieber. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes. Metab.. 2007;9:648-659
  • 46 M.C. Riddle, J. Rosenstock, J. Gerich, on behalf of the INsulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080-3086
  • 47 M.C. Riddle. The Treat-to-Target Trial and related studies. Endocr. Pract.. 2006;12(Suppl. 1):71-79
  • 48 K. Raslova, M. Bogoev, I. Raz, et al. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract.. 2004;66:193-201
  • 49 K. Hermansen, M. Davies, T. Derezinski, et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naïve people with type 2 diabetes. Diabetes Care. 2006;29:1269-1274
  • 50 A. Philis-Tsimikas, G. Charpentier, P. Clauson, et al. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther. 2006;28:1569-1581
  • 51 K. Rašlová, S.C. Tamer, P. Clauson, D. Karl. Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index. Clin Drug Investig.. 2007;27:279-285
  • 52 A. Philis-Tsimikas. Tolerability, safety and adherence to treatment with insulin detemir injection in the treatment of type 2 diabetes. Patient Prefer. Adherence. 2008;2:323-332
  • 53 J. Rosenstock, M. Davies, P.D. Home, et al. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia. 2008;51:408-416
  • 54 P. Hollander, J. Cooper, J. Bregnhøj, C.B. Pedersen. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther. 2008;30:1976-1987
  • 55 J.H. Devries, M. Nattrass, T.R. Pieber. Refining basal insulin therapy: what have we learned in the age of analogues?. Diabetes Metab. Res. Rev.. 2007;23:441-454
  • 56 C. Koenen. How do detemir and glargine compare when added to oral agents in insulin-naive patients with type 2 diabetes mellitus?. Nat. Clin. Pract. Endocrinol. Metab.. 2008;4:E1
  • 57 J.P. Le Floch, M. Levy, H. Mosnier-Pudar, et al. Comparison of once-versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes: assessment of detemir administration in a progressive treat-to-target trial (ADAPT). Diabetes Care. 2009;32:32-37
  • 58 P. Fontaine, H. Gin, M. Pinget, et al. Effect of insulin detemir dose frequency on clinical outcomes in patients with diabetes in PREDICTIVE. Adv. Ther.. 2009;26:535-551
  • 59 D.G. Bruce, D.J. Chisholm, L.H. Storlien, E.W. Kraegen. Physiological importance of deficiency in early prandial insulin secretion in non-insulin-dependent diabetes. Diabetes. 1988;37:736-744
  • 60 M. Davies, F. Storms, S. Shutler, et al. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care. 2005;28:1282-1288
  • 61 M. Davies, F. Lavalle-Gonzalez, F. Storms, R. Gomis. Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial. Diabetes Obes. Metab.. 2008;10:387-399
  • 62 L. Meneghini, C. Koenen, W. Weng, J.-L. Selam. The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes–results of the randomized, controlled PREDICTIVE™ 303 study. Diabetes Obes. Metab.. 2007;9:902-913
  • 63 J.L. Selam, C. Koenen, W. Weng, L. Meneghini. Improving glycemic control with insulin detemir using the 303 Algorithm in insulin naive patients with type 2 diabetes: a subgroup analysis of the US PREDICTIVE 303 study. Curr. Med. Res. Opin.. 2008;24:11-20
  • 64 S.V. Hordern, J.E. Wright, A.M. Umpleby, et al. Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp. Diabetologia. 2005;48:420-426
  • 65 A.M. Hennige, T. Sartorius, O. Tschritter, et al. Tissue selectivity of insulin detemir action in vivo. Diabetologia. 2006;49:1274-1282
  • 66 O. Tschritter, A.M. Hennige, H. Preissl, et al. Cerebrocortical beta activity in overweight humans responds to insulin detemir. PLoS ONE. 2007;2:e1196

Footnotes

a University of Miami Miller School of Medicine, Miami, Florida, USA

b Center for Diabetes and Metabolism, Fachklinik, Bad Heilbrunn, Germany

c Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts, USA

* Corresponding author. Luigi Meneghini. Division of Endocrinology & Diabetes, University of Miami School of Medicine, Diabetes Research Institute, 1450 NW 10th Avenue, Miami, Florida 33136, USA. Tel.: +1 305-243-5366; fax: +1 305-243-1200